MICROBIOTIX, INC.
Small molecule inhibitors targeting RVFV endonuclease for prophylaxis and treatment of Rift Valley Fever Virus infections
- Sector
- Biotech
- Headquarters
- Worcester, MA
- Total capital
- $74.8M
- Federal grants
- $51.1M
- 95 awards · 2014–2026
- Rank in peer group#22 of 514
- Private capital raised
- None on recordNo Form D filings on SEC EDGAR. Some raises are not filed.
- Federal contracts
- $23.7M
- 4 awards · Defense, Health and Human S
- Rank in Biotech#37 of 4373
- Granted patents
- 1
- 33 pending · first 2017
- Rank in peer group#186 of 514
Capital timeline
Latest events
- Federal grantHealth and Human S · Phase II · Discovery of Bunyaviral Endonuclease Inhibitors for Anti Viral$969K
- Federal grantHealth and Human S · Phase I · Novel Benzyl-Piperidine antifungal agents to treat intractable Mucorales infections$300K
- Federal grantHealth and Human S · Phase I · Development of well tolerated novel Inhibitors of drug resistant CMV$299K
- Federal grantHealth and Human S · Phase II · Discovery of Bunyaviral Endonuclease Inhibitors for Anti Viral$977K
- Federal grantHealth and Human S · Phase I · Proof of concept experiments for T3SS inhibitors against burn wound infections$300K
- Federal grantHealth and Human S · Phase I · Development of antibody drug conjugates as pan-filo antivirals$287K
- Federal grantHealth and Human S · Phase I · Proof of concept experiments for T3SS inhibitors against burn wound infections$300K
Show 92 earlier federal awards
- Federal grantHealth and Human S · Phase I · Development of antibody drug conjugates as pan-filo antivirals$300K
- Federal grantHealth and Human S · Phase I · Discovery of Bunyaviral Endonuclease Inhibitors for Antiviral Therapy$272K
- Federal grantHealth and Human S · Phase II · Screening for rAAV transduction enhancers$988K
- Federal contractHealth and Human S · To Develop The Ppz Series Of Small Molecule Pan-filovirus Entry Inhibitors Through Lead Optimization, Selection Of A Preclinical Candidate, And Ind-enabling Preclinical Studies.$8.8M
- Federal grantHealth and Human S · Phase I · Discovery of Bunyaviral Endonuclease Inhibitors for Antiviral Therapy$297K
- Federal grantHealth and Human S · Phase I · Discovery of Bunyaviral Endonuclease Inhibitors for Antiviral Therapy$569K
- Federal grantHealth and Human S · Phase I · Type 3 secretion system inhibitors to treat Pseudomonas aeruginosa keratitis$300K
- Federal grantHealth and Human S · Phase II · Development of Filociclovir for the Treatment of Ocular Adenoviral Infections and Keratoconjunctivitis$713K
- Federal grantHealth and Human S · Phase II · Screening for rAAV transduction enhancers$987K
- Federal grantHealth and Human S · Phase II · Optimization of novel pyranopyridine efflux pump inhibitors$1M
- Federal grantHealth and Human S · Phase II · Novel Spectinamide Antibiotics for the Treatment of MDR/XDR Tuberculosis$997K
- Federal grantHealth and Human S · Phase I · Development of a novel broad-spectrum inhibitor of non-polio enteroviruses associated with acute flaccid myelitis$287K
- Federal grantHealth and Human S · Phase I · Inhibitors of T3SS translocon assembly to combat multi-drug resistant P. aeruginosa$300K
- Federal grantHealth and Human S · Phase I · Development of a New Class of Hepatitis B Virus Inhibitors that Induce a Novel Defective Nucleocapsid Phenotype$298K
- Federal grantHealth and Human S · Phase II · Development of Filociclovir for the Treatment of Ocular Adenoviral Infections and Keratoconjunctivitis$1.5M
- Federal grantHealth and Human S · Phase II · Development of Filociclovir for the Treatment of Ocular Adenoviral Infections and Keratoconjunctivitis$750K
- Federal grantHealth and Human S · Phase II · Screening for rAAV transduction enhancers$3M
- Federal grantHealth and Human S · Phase II · Screening for rAAV transduction enhancers$1.0M
- Federal grantHealth and Human S · Phase II · Novel Plasmodial Surface Anion Channel Inhibitors as Antimalarial Drugs$982K
- Federal grantHealth and Human S · Phase I · Discovery of Enterovirus D68 2A protease inhibitors for antiviral therapy$300K
- Federal grantHealth and Human S · Phase I · Development of a novel broad-spectrum inhibitor of non-polio enteroviruses associated with acute flaccid myelitis$585K
- Federal grantHealth and Human S · Phase I · Development of a novel broad-spectrum inhibitor of non-polio enteroviruses associated with acute flaccid myelitis$298K
- Federal grantHealth and Human S · Phase II · Novel Spectinamide Antibiotics for the Treatment of MDR/XDR Tuberculosis$1M
- Federal grantHealth and Human S · Phase II · Optimization of novel pyranopyridine efflux pump inhibitors$981K
- Federal grantHealth and Human S · Phase I · Inhibitors of T3SS translocon assembly to combat multi-drug resistant P. aeruginosa$299K
- Federal grantHealth and Human S · Phase I · Development of a New Class of Hepatitis B Virus Inhibitors that Induce a Novel Defective Nucleocapsid Phenotype$597K
- Federal grantHealth and Human S · Phase I · Development of a New Class of Hepatitis B Virus Inhibitors that Induce a Novel Defective Nucleocapsid Phenotype$298K
- Federal contractHealth and Human S · To Develop Phenoxyacetamide T3SS Inhibitors As Adjunctive Agents To Antibacterial Therapy For Mdr P. Aeruginosa Infections.$7.3M
- Federal grantHealth and Human S · Phase I · Discovery of Enterovirus D68 2A protease inhibitors for antiviral therapy$300K
- Federal grantHealth and Human S · Phase I · Discovery of Enterovirus D68 2A protease inhibitors for antiviral therapy$600K
- Federal grantHealth and Human S · Phase II · Novel Plasmodial Surface Anion Channel Inhibitors as Antimalarial Drugs$992K
- Federal grantHealth and Human S · Phase II · Novel Spectinamide Antibiotics for the Treatment of MDR/XDR Tuberculosis$1.0M
- Federal grantHealth and Human S · Phase II · Optimization of novel pyranopyridine efflux pump inhibitors$988K
- Federal grantHealth and Human S · Phase I · Novel Small Molecule Therapeutics Inhibiting Zika Virus Infection$298K
- Federal grantHealth and Human S · Phase I · EF-Tu binding Tetrazoles targeting MDR Neisseria gonorrhoeae$300K
- Federal grantHealth and Human S · Phase I · Discovery of Zika virus therapeutics using a replicon assay$285K
- Federal grantHealth and Human S · Phase I · Synergistic panfiloviral entry inhibiting antibody drug conjugates$300K
- Federal grantHealth and Human S · Phase II · Novel Plasmodial Surface Anion Channel Inhibitors as Antimalarial Drugs$1.0M
- Federal grantHealth and Human S · Phase I · Inhibitors of virus glycoprotein-LAMP1 receptor binding for Lassa virus therapy$296K
- Federal grantHealth and Human S · Phase I · Novel Small Molecule Therapeutics Inhibiting Zika Virus Infection$300K
- Federal grantHealth and Human S · Phase I · Novel Small Molecule Therapeutics Inhibiting Zika Virus Infection$598K
- Federal grantHealth and Human S · Phase I · Discovery of Zika virus therapeutics using a replicon assay$585K
- Federal grantHealth and Human S · Phase I · Discovery of Zika virus therapeutics using a replicon assay$300K
- Federal grantHealth and Human S · Phase I · EF-Tu binding Tetrazoles targeting MDR Neisseria gonorrhoeae$597K
- Federal grantHealth and Human S · Phase I · EF-Tu binding Tetrazoles targeting MDR Neisseria gonorrhoeae$297K
- Federal grantHealth and Human S · Phase I · Aminospectinomycin antibacterials for the treatment of antibiotic-resistant gonorrhea and other bacterial STDs$289K
- Federal grantHealth and Human S · Phase I · Development of small molecule TLR5 inhibitors for rheumatoid arthritis therapy$208K
- Federal grantHealth and Human S · Phase I · Inhibitors of Pseudomonas aeruginosa efflux pumps to combat multi-drug resistance$295K
- Federal grantHealth and Human S · Phase I · Synergistic panfiloviral entry inhibiting antibody drug conjugates$600K
- Federal grantHealth and Human S · Phase I · Synergistic panfiloviral entry inhibiting antibody drug conjugates$300K
- Federal grantHealth and Human S · Phase I · Inhibitors of virus glycoprotein-LAMP1 receptor binding for Lassa virus therapy$596K
- Federal grantHealth and Human S · Phase I · Inhibitors of virus glycoprotein-LAMP1 receptor binding for Lassa virus therapy$299K
- Federal grantHealth and Human S · Phase I · Screening for rAAV transduction enhancers$291K
- Federal contractDefense · Develop Novel And Innovative Small Molecule Therapeutics To Treat (post-exposure Therapeutic) Infections By Both Filovirus Family Members (ebola Viruses And Marburg Viruses)$2.6M
- Federal grantHealth and Human S · Phase I · Development of small molecule TLR5 inhibitors for rheumatoid arthritis therapy$225K
- Federal grantHealth and Human S · Phase I · Aminospectinomycin antibacterials for the treatment of antibiotic-resistant gonorrhea and other bacterial STDs$297K
- Federal grantHealth and Human S · Phase I · T3SS needle protein inhibitors for the treatment of P. aeruginosa infection$298K
- Federal grantHealth and Human S · Phase I · Inhibitors of the viral nucleoprotein-polymerase co-factor interaction for human RSV and MPV therapy$285K
- Federal grantHealth and Human S · Phase I · Inhibitors of Pseudomonas aeruginosa efflux pumps to combat multi-drug resistance$594K
- Federal grantHealth and Human S · Phase I · Novel beta-lactams as inhibitors of ebola virus infections$297K
- Federal grantHealth and Human S · Phase I · Inhibitors of Pseudomonas aeruginosa efflux pumps to combat multi-drug resistance$299K
- Federal grantHealth and Human S · Phase I · Screening for rAAV transduction enhancers$591K
- Federal grantHealth and Human S · Phase I · Screening for rAAV transduction enhancers$300K
- Federal grantHealth and Human S · Phase II · Optimization of novel pyranopyridine efflux pump inhibitors$743K
- Federal grantHealth and Human S · Phase I · T SS needle protein inhibitors for the treatment of P aeruginosa infection$601K
- Federal grantHealth and Human S · Phase I · T3SS needle protein inhibitors for the treatment of P. aeruginosa infection$303K
- Federal grantHealth and Human S · Phase I · Inhibitors of the viral nucleoprotein polymerase co factor interaction for human RSV and MPV therapy$585K
- Federal grantHealth and Human S · Phase I · Inhibitors of the viral nucleoprotein-polymerase co-factor interaction for human RSV and MPV therapy$300K
- Federal grantHealth and Human S · Phase I · GPCR antagonists as anti-Ebola virus entry inhibitors$298K
- Federal grantHealth and Human S · Phase I · Novel beta lactams as inhibitors of ebola virus infections$602K
- Federal grantHealth and Human S · Phase I · Novel beta-lactams as inhibitors of ebola virus infections$304K
- Federal grantHealth and Human S · Phase I · Antibiotic potentiators maximizing the formation of open- channel OprF-type outer membrane porins$287K
- Federal grantHealth and Human S · Phase II · Novel spectinamide antibiotics for the treatment of MDR/XDR tuberculosis$982K
- Federal grantHealth and Human S · Phase I · Novel filovirus entry inhibitors based on a pseudo-symmetrical biphenyl core$288K
- Federal grantHealth and Human S · Phase II · Optimization of novel pyranopyridine efflux pump inhibitors$783K
- Federal grantHealth and Human S · Phase I · Lipoprotein synthesis inhibitors for multi-drug resistant Gram-negative therapy$288K
- Federal grantHealth and Human S · Phase II · Novel Plasmodial Surface Anion Channel Inhibitors as Antimalarial Drugs$690K
- Federal grantHealth and Human S · Phase I · GPCR antagonists as anti-Ebola virus entry inhibitors$597K
- Federal grantHealth and Human S · Phase I · Small Molecule Inhibitors of trans-Translation with Broad Spectrum Antibacterial$295K
- Federal grantHealth and Human S · Phase I · Antibiotic potentiators maximizing the formation of open- channel OprF-type outer membrane porins$570K
- Federal grantHealth and Human S · Phase I · GPCR antagonists as anti-Ebola virus entry inhibitors$299K
- Federal grantHealth and Human S · Phase I · Antibiotic potentiators maximizing the formation of open- channel OprF-type outer membrane porins$283K
- Federal grantHealth and Human S · Phase II · Novel spectinamide antibiotics for the treatment of MDR/XDR tuberculosis$988K
- Federal grantHealth and Human S · Phase I · Novel Inhibitors Targeting Early Steps of Human Cytomegalovirus Replication$290K
- Federal grantHealth and Human S · Phase I · Novel filovirus entry inhibitors based on a pseudo-symmetrical biphenyl core$577K
- Federal grantHealth and Human S · Phase II · Optimization of novel pyranopyridine efflux pump inhibitors$961K
- Federal grantHealth and Human S · Phase I · Novel filovirus entry inhibitors based on a pseudo-symmetrical biphenyl core$289K
- Federal grantHealth and Human S · Phase I · Lipoprotein synthesis inhibitors for multi-drug resistant Gram-negative therapy$288K
- Federal grantHealth and Human S · Phase I · New small molecule inhibitors of arenaviruses$298K
- Federal grantHealth and Human S · Phase I · New heterocyclic inhibitors of filoviruses$300K
- Federal grantHealth and Human S · Phase II · Novel Plasmodial Surface Anion Channel Inhibitors as Antimalarial Drugs$644K
- Federal contractDefense · Project Funding$5.1M
Federal awards are summed by year (99 awards); hover a bar for the split. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 514 peers
Line = medianBiotech · Molecule
- Federal grants#22 · top 4%
- Granted patents#186 · top 36%
- Linked publications#13 · top 3%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
No founders are linked to this company yet.
Founders appear once a person is matched to the company through its own patents, grants or filings. We never infer people from social profiles.
Checked: USPTO inventors; federal award principal investigators; SEC Form D related persons · Oct 23, 2026
Claim this profile to add your teamWhat it has protected
USPTO · 1 granted of 34- PendingCompositions And Methods Of Treating Or Preventing Ocular Infections With FilociclovirUSPTOApplication 17622613
- PendingCombination Drug Treatment For Human CytomegalovirusUSPTOApplication 17438452
- GrantedAntimicrobial PotentiatorsUSPTOUS 9,540,389
Show all 34 patent records
- Compositions And Methods Of Treating Or Preventing Ocular Infections With FilociclovirNov 24, 2022 · Application 17622613Pending
- Combination Drug Treatment For Human CytomegalovirusMay 19, 2022 · Application 17438452Pending
- Antimicrobial PotentiatorsJan 10, 2017 · US 9,540,389Granted
- Inhibitors Of Bacterial Type III Secretion SystemApplication 63349173Pending
- Compositions And Methods Of Treating Or Preventing Ocular Infections With FilociclovirApplication PCTUS2020039258Pending
- Combination Drug Treatment For Human CytomegalovirusApplication PCTUS2020022332Pending
- Combination Drug Treatment For Human CytomegalovirusApplication 62817069Pending
- Inhibition Of Adenovirus With FilociclovirApplication 62815630Pending
- Multimeric Inhibitors Of Bacteril Type III Secretion SystemApplication PCTUS2018030389Pending
- Multimeric Inhibitors Of Bacterial Type III Secretion SystemApplication 62500230Pending
- Broad Spectrum Inhibitors Of FilovirusesApplication 62430205Pending
- Antimicrobial PotentiatorsApplication PCTUS2014036712Pending
- Aminoalkyl Phenol Ether Inhibitors Of Influenza A VirusApplication PCTUS2012065582Pending
- Antifungal CompoundsApplication PCTUS2012055683Pending
- Antimicrobial CompoundsApplication PCTUS2012055678Pending
- Antimicrobial CompoundsApplication PCTUS2012055679Pending
- Antimicrobial CompoundsApplication PCTUS2012055677Pending
- Inhibitors Of Bacterial Type III Secretion SystemApplication PCTUS2012046676Pending
- Inhibitors Of Bacterial Type III Secretion SystemApplication PCTUS2012046693Pending
- Inhibitors Of Viral Entry Into Mammalian CellsApplication PCTUS2011051389Pending
- Inhibitors Of Botulinum NeurotoxinsApplication PCTUS2010046314Pending
- Inhibitors Of Filovirus Entry Into Host CellsApplication PCTUS2010041632Pending
- Compounds With Antifungal PropertiesApplication 19487933Pending
- Inhibitors Of BunyavirusesApplication PCTUS2025056445Pending
- Inhibitors Of Bacterial Type III Secretion SystemApplication PCTUS2010030120Pending
- Inhibitors Of Bacterial Biofilm FormationApplication PCTUS2009003086Pending
- Polar Ester Prodrugs Of Heterocyclic Hybrid Antibacterial Compounds And Salts ThereofApplication PCTUS2007017200Pending
- Antibacterial Pyrazole Carboxylic Acid HydrazidesApplication PCTUS2003028392Pending
- Methods And Compositions For Treating Flavivirus-mediated DiseaseApplication PCTUS2002034659Pending
- Methods An Compositions For Treating Rotovirus-mediated DiseaseApplication PCTUS2002034664Pending
- Inhibitors Of Bacterial Type III Secretion SystemApplication PCTUS2023024416Pending
- Novel Heterocyclic Antibacterial CompoundsApplication PCTUS2002019148Pending
- Compounds With Antifungal PropertiesApplication 63469306Pending
- Broad Spectrum Inhibitors Of CytomegalovirusApplication PCTUS2023013580Pending
Recent research by its founders
- <i>trans</i> -Translation inhibitors that kill <i>M. tuberculosis</i> and pathogenic Non-tuberculous Mycobacteria have a dual mechanism of action20261 cites
- trans-Translation inhibitors that kill Mycobacterium tuberculosis and pathogenic non-tuberculous mycobacteria also disrupt metal homeostasis20260 cites
- Identification and Characterization of a Metal Binding-Independent Rift Valley Fever Virus Endonuclease Inhibitor20250 cites
Related companies, and why
- Chicago Biosolutions, Inc.Shares a founder: RONG, LIJUN
- SANARIA INC.Similar federal contract value in Biotech · $25M in contracts
- Myriad GeneticsSimilar federal contract value in Biotech · $25M in contracts
- PARABON NANOLABS, INC.Similar federal contract value in Biotech · $24.7M in contracts
- Biospyder Technologies, Inc.Similar federal contract value in Biotech · $23.1M in contracts
- HUMANETICS CORPSimilar federal contract value in Biotech · $22M in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .